The Oncology Institute, Inc. TOI Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Other Operating Income by Business | |||||
| Clinical trials & other | $4.24M-39.5% | $7M+14.6% | $6.11M+9.5% | $5.58M+4.0% | |
| Patient services | $17.7M+45.8% | $12.14M-55.9% | $27.53M-2.2% | $28.15M+29.7% | |
| Total operating revenue by Product | |||||
| Capitated revenue | $80.48M+17.2% | $68.69M-2.4% | $70.37M+14.7% | $61.34M+13.0% | |
| Clinical trials & other | $4.56M-47.0% | $8.61M+24.8% | $6.9M+8.6% | $6.36M-0.4% | |
| FFS revenue | $148.51M+9.0% | $136.2M-4.8% | $143.13M+35.7% | $105.44M+51.1% | |
| Patient services | $228.99M+11.8% | $204.88M-4.0% | $213.5M+28.0% | $166.79M+34.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does The Oncology Institute, Inc. break its business down?
- The Oncology Institute, Inc. (TOI) reports other operating income by business across 3 parts — Clinical trials & other, Patient services and Specialty pharmacy. Each is extracted from the segment footnotes and tracked over time.
- Where does The Oncology Institute, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in The Oncology Institute, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
